KraneShares Hang Seng TECH Index ETF vs Zoetis Inc — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $11.8 (market cap $45.04M), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 670.5× KraneShares Hang Seng TECH Index ETF's market cap, and Zoetis Inc pays a 2.9% dividend while KraneShares Hang Seng TECH Index ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Hang Seng TECH Index ETF for 44 Days and Zoetis Inc for 70 Days on average.
| KTEC | ZTS | |
|---|---|---|
Market Cap | $45.04M | $30.20B |
Volume | 29,043 | 6,175,327 |
Sector | Sector/Thematic | Health |
52-Week High | $18.73 | $147.53 |
52-Week Low | $11.41 | $69.09 |
Typical Hold Time | 44 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Trailing returns across standard periods
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →